CMS
Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests
Tests like MDxHealth's SelectMDx, Bio-Techne's ExoDx Prostate, and various PSA scoring algorithms would be reimbursed if they pass a technical assessment.
Medicare Contractor's Final Coverage Decision on NGS Cancer Testing Appeases Industry Stakeholders
Premium
The LCD covers tests that are FDA approved or cleared, have published analytical validity evidence, or are certified by a third party to be aligned with NYSDOH's criteria.Â
Senate Bill Proposes to Expand Medicare Coverage for Hereditary Cancer Testing
Legislators sponsoring the bill hope the move will improve access to cancer screenings, preventative surgeries, and save lives.
CMS No Longer Reimbursing Interpace Bio Thyroid Tests; Firm's Rights Offering Terminated
CMS has issued a new billing policy and will no longer reimburse for the use of Interpace's ThyGeNext and ThyraMir thyroid cancer tests under certain conditions.
Banner Year for Blood-Based Cancer Screening in 2021, but Reimbursement and Utility Hurdles Loom
Premium
New companies claimed stakes during the year, established firms solidified their plans and data, and Grail launched the first genomic multi-cancer early detection test.